BioNTech slides 20.5% as 2026 revenue outlook and founder transition weigh on shares

BioNTech SE (BNTX) is down 20.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to BioNTech’s 2026 outlook, which guided to lower total revenue as COVID-19 vaccine demand continues to fade in key markets. Investor concerns may have been compounded by the company’s disclosure that its co-founders plan to transition to a new, independent mRNA-focused venture by the end of 2026.

Details:

BioNTech guided 2026 total revenues to €2.0 billion–€2.3 billion, citing expectations for lower COVID-19 vaccine revenue in both the U.S. and Europe.

The company reported Q4 2025 revenue of €907.4 million versus €1,190.0 million in the prior-year quarter, attributing the decline primarily to reduced COVID-19 vaccine demand.

BioNTech said co-founders Uğur Şahin and Özlem Türeci plan to establish an independent company focused on next-generation mRNA innovations, with a management transition targeted by end of 2026.

Despite the drop, BioNTech ended 2025 with €17.2 billion in cash, cash equivalents and security investments, while projecting elevated 2026 adjusted R&D spending of €2.2 billion–€2.5 billion.

Sources:

U.S. SEC (EDGAR), BioNTech (earnings release/Form 6-K exhibit)

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BNTX Hedge Fund Activity

We have seen 138 institutional investors add shares of $BNTX stock to their portfolio, and 144 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BAILLIE GIFFORD & CO removed 6,634,492 shares (-84.2%) from their portfolio in Q4 2025, for an estimated $631,603,638
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,746,944 shares (-36.1%) from their portfolio in Q4 2025, for an estimated $166,309,068
PFIZER INC removed 1,658,361 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $157,875,967
JANE STREET GROUP, LLC added 1,164,203 shares (+590.9%) to their portfolio in Q4 2025, for an estimated $110,832,125
ALTRINSIC GLOBAL ADVISORS LLC removed 496,771 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $48,991,556
D. E. SHAW & CO., INC. added 488,552 shares (+inf%) to their portfolio in Q4 2025, for an estimated $46,510,150
FMR LLC added 480,114 shares (+8.8%) to their portfolio in Q4 2025, for an estimated $45,706,852

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BNTX Analyst Ratings

Wall Street analysts have issued reports on $BNTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
Morgan Stanley issued a "Overweight" rating on 10/10/2025

To track analyst ratings and price targets for $BNTX, check out Quiver Quantitative's $BNTX forecast page.

$BNTX Price Targets

Multiple analysts have issued price targets for $BNTX recently. We have seen 5 analysts offer price targets for $BNTX in the last 6 months, with a median target of $131.0.

Here are some recent targets:

Asad Haider from Goldman Sachs set a target price of $142.0 on 01/16/2026
Robert Burns from HC Wainwright & Co. set a target price of $140.0 on 11/10/2025
David Dai from UBS set a target price of $117.0 on 11/06/2025
Jessica Fye from JP Morgan set a target price of $120.0 on 10/23/2025
Terence Flynn from Morgan Stanley set a target price of $131.0 on 10/10/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.